Meeting
2017 ASCO Annual Meeting
ACRIN 6698 trial: Quantitative diffusion-weighted MRI to predict pathologic response in neoadjuvant chemotherapy treatment of breast cancer.
Authors
Savannah C. Partridge
University of Washington Seattle Cancer Care Alliance, Seattle, WA
Savannah C. Partridge , Zheng Zhang , David C Newitt , Jessica E Gibbs , Thomas L Chenevert , Mark Alan Rosen , Patrick J Bolan , Helga Marques , Laura Esserman , Nola M Hylton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Clinical Trial Registration Number
NCT01564368
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11520)
DOI
10.1200/JCO.2017.35.15_suppl.11520
Abstract #
11520
Poster Bd #
220
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
First Author: Roberto Antonio Leon-Ferre
Poster
2023 ASCO Annual Meeting
Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers.
First Author: Sara P. Myers
Poster
2024 ASCO Annual Meeting
A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).
First Author: Rana R. McKay
Poster
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
First Author: Tarek Mohamed Ahmed Abdel-Fatah